贝纳利祖马布治疗对COPD呼吸道微生物群的影响
Koirobi Haldar1, Vijay Mistry1, Mathew Richardson1
1Institute for Lung Health, NIHR, BRC, Department of Respiratory Sciences, College of Life Sciences, University of Leicester, Leicester, UK.
ERJ open research
|April 8, 2025
概括
贝纳利祖马布有效地降低了COPD患者的乙氨基酸,但没有改变呼吸道微生物群. 这项研究研究了本拉利祖马布对慢性阻塞性肺病 (COPD) 炎症和唾液微生物群的影响.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 大约三分之一的慢性阻塞性肺病 (COPD) 患者表现出一种eosinophilic炎症表型.
- 贝纳利祖马布是一种单克隆抗体,向介素-5受体α子单元,诱导快速的乙氨基基酸枯竭.
- 这项研究探讨了本拉利祖马布诱导的免疫调节对COPD呼吸道微生物组的潜在影响.
研究的目的:
- 为了研究本拉利祖马布治疗对炎症的影响.
- 评估本拉利祖马布对COPD患者唾液微生物群的影响.
主要方法:
- 在52周的GALATHEA试验中分析了94名COPD患者的唾液样本.
- 随机分配到安慰剂,100毫克本拉利祖马布或30毫克本拉利祖马布.
- 16S rRNA基因测序用于唾液微生物群分析和多样性分析;细胞计数和媒介分析的线性混合模型.
主要成果:
- 贝纳利祖马布治疗显著降低了血液和唾液中异osinophil 数量以及异osinophil 衍生的血清介质.
- 在唾液微生物组的组成或多样性中没有观察到任何显著的变化.
- 在本拉利祖马布组中,乙氨基小细胞的减少是剂量依赖的,并且在统计学上显著.
结论:
- 用本拉利祖马布向性降低乙酸性炎症并没有影响COPD患者的呼吸道微生物群.
- 这项研究表明,乙酸性炎症调节不会直接改变液微生物群的组成或多样性.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
144
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
144
01:17Drugs Used in Lower Respiratory Disorders: Overview
278
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
278
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
182
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
182
01:19Antiasthma Drugs: Leukotriene Modifiers
172
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
172
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
165
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
165
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K